Journal of Infectious Diseases & Preventive Medicine 1 J Infect Dis Preve Med, Vol. 10 Iss. 4 No: 1000267 OPEN ACCESS Freely available online Research Article Correspondence to: Padamnabhi SN, Department of Botany, The Maharaja Sayajirao University of Baroda, Gujarat, India, E-mail: drnagar@gmail. com Received: 15-Apr-2022, Manuscript No. JADPR-22-16884; Editor assigned: 19-Apr-2022, PreQC No. JADPR-22-16884 (PQ); Reviewed: 03-May- 2022, QC No. JADPR-22-16884; Revised: 09-May-2022, Manuscript No. JADPR-22-16884 (R); Published: 16-May-2022, DOI: 10.35841/2329- 8731.22.10.267. Citation: Vanzara A, Patel R, Patel A, Patel N, Yadav K, Nagar PS (2022) Liquiritin from Glycirrhyza glabra L (Fabaceae): A Natural Drug, as a Potent Inhibitor for SARS-CoV-2. J Infect Dis Preve Med. 10:267. Copyright: © 2022 Vanzara A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Liquiritin from Glycirrhyza glabra L (Fabaceae): A Natural Drug, as a Potent Inhibitor for SARS-CoV-2 Akash Vanzara 1 , Ravi Patel 1 , Amisha Patel 2 , Nimisha Patel 1 , Kapil Yadav 1 , Padamnabhi S. Nagar 1* 1 Department of Botany, The Maharaja Sayajirao University of Baroda, Gujarat, India; 2 P. G. Department of Biosciences, Sardar Patel University, Anand, Gujarat, India INTRODUCTION In the wake of COVID-19 outbreak, mankind suffering with high risk of safety and health issues all over world. It was began at the end of year 2019, and still continues to causing major backdrop to the world. It affects most to the health sector, wherein globally 17,512,049 active cases and 677,543 deaths recorded at the end of August-2020 [1]. Presently there are certain drugs which prescribed by health expertise across world viz. remdesivir, hydroxychloroquine, dexamethasone, azithromycin. As per emergency protocol, first patient, 35 year old from Washington, affected with COVID-19 showed improvement in pneumonia after 7 days of treatment with remdesivir [2]. Seven critically ill patients were treated with much compassionate drug remdesivir in Seattle USA [3]. In more extensive study, 10-day course of a drug remdesivir treatment by intravenous administration at the dose of 200 mg on day 1, followed by 100 mg daily, 68% of patients with COVID-19 showed clinical improvement [4]. Hydroxychloroquine is generally used to treat malaria, a lupus erythematosus, and rheumatoid arthritis. However, according to WHO, 2020b [5], drug does not reduce the death of hospitalized COVID-19 patients. As per preliminary study conducted by UK national clinical trial, dexamethasone would help critically ill patients, but patients on mechanical oxygen support, reduces mortality rate about one third whereas patient who requires only oxygen, mortality rate was observed as one fifth [6]. According to retrospective multicentre cohort study of patients in New York state, probability of death among the group of patients receiving combined treatment of hydroxychloroquine and azithromycin was 25.7% wherein with alone treatment of azithromycin was 10%. Furthermore, in adjustment Cox proportional hazard models, patients neither receive combination of drug nor alone one, there were no significant difference in mortality [7]. Nature has always overwhelmed us with many new and unique bioactive compounds which possess potent activity against various disease and infection [8]. Hence, there is prerequisite of scientific ABSTRACT Novel Corona virus-2 (COVID-19) is spreading and causing major damage around the globe and constantly increasing daily. There is a prerequisite for expeditious development of safe and efficient drugs for such a contagious disease. In this regard, the utilization of a computational approach with an aim to provide potent enzyme inhibitors derived from natural resources will give a providential therapy. The present study investigated one of the promising plants namely Glycyrrhiza glabra L. It has various medicinal properties viz. anti-inflammatory, anti-cancer, anti-demulcent, expectorant, etc. In-Silico analysis of liquiritin against SARS-CoV-2 Mpro was carried out using Autodock 4.2.6 and results were compared with presently prescribed drugs i.e. dexamethasone, remdesivir, hydroxychloroquine, and azithromycin. The binding energy of liquiritin was found to be -6.62 kcal/mol. It shows the presence of hydrogen bond, hydrophobic interaction, and electrostatic interaction with six active residues THR26, GLY143, CYS145, HIS 164, GLU166, and GLN189. Comparative studies investigated that dexamethasone, remdesivir, hydroxychloroquine, and azithromycin have four (THR26, GLY143, CYS145, GLU166), three (CYS145, GLU166, GLN189), four (GLY143, CYS145, HIS 164, GLN189), and two (GLU166, GLN189) identical active residues, respectively. The present study recommended liquiritin as a potential candidate against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as it is naturally derived and has tremendous traditional usage against various diseases. However, in-vitro and in-vivo studies are required to prove its efficacy. Keywords: Liquiritin; SARS-COV-2; Medicinal plant; Natural drug